Efficacy and safety of regorafenib versus dinutuximab with chemotherapy in Chinese children with neuroblastoma

Authors

  • Kun Dong Department of Neurosurgery, Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300150, China https://orcid.org/0000-0003-2688-0037
  • Guan Wang Department of Neurosurgery, Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300150, China
  • Zeng Liang Wang Department of Neurosurgery, Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300150, China https://orcid.org/0000-0002-0079-2971
  • Xueyan Wang Department of Neurosurgery, Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300150, China https://orcid.org/0000-0002-8653-4104

DOI:

https://doi.org/10.3329/bjp.v14i1.38807

Keywords:

Chemotherapy, Children, Chinese, Dinutuximab, Neuroblastoma, Regorafenib

Abstract

The objective of the present study was to evaluate the efficacy and safety of regorafenib in comparison with dinutuximab with chemotherapy in Chinese children with advanced neuroblastoma. The patients aged less than 16 years who were histologically diagnosed with advanced neuroblastoma were enrolled and randomized to receive either regorafenib plus best supportive care or dinutuximab plus chemotherapy plus best supportive care in a 1:1 ratio. The tumor response assessment was made in accordance with modified international neuroblastoma response criteria. Adverse events were also assessed. Regorafenib showed prolonged overall survival and progression-free survival than who received dinutuximab plus chemotherapy (overall survival: median 32.3 months versus 27.2 months; hazard ratio = 0.45; 95% CI 0.11-0.13, p<0.001; progression-free survival: stratified hazard ratio = 0.48; 95% CI 0.11-0.14; p<0.01).  Moreover, the overall response rate was greater in patients treated with regorafenib as compared to dinutuximab group. Regorafenib appears efficacious and has a manageable safety profile in Chinese children with advanced neuroblastoma.

Downloads

Download data is not yet available.
Abstract
3
Download
2 Read
1

Downloads

Additional Files

Published

2019-02-07

How to Cite

Dong, K., G. Wang, Z. L. Wang, and X. Wang. “Efficacy and Safety of Regorafenib Versus Dinutuximab With Chemotherapy in Chinese Children With Neuroblastoma”. Bangladesh Journal of Pharmacology, vol. 14, no. 1, Feb. 2019, pp. 32-35, doi:10.3329/bjp.v14i1.38807.

Issue

Vol. 14 No. 1 (2019)

Section

Clinical Trial

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).